An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Indication: As an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH)
CADTH recommends that Evkeeza be reimbursed by public drug plans as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)–lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH) if certain conditions are met.
Evkeeza should only be covered to treat patients aged 5 years and older with a diagnosis of HoFH and extremely high levels of LDL-C (sometimes referred to as bad cholesterol) despite receiving other cholesterol-lowering treatments.
Evkeeza should only be reimbursed if prescribed by specialists with experience in managing HoFH and if the cost of Evkeeza is reduced. Evkeeza may only be prescribed for 24 weeks the first time it is used. To continue treatment with Evkeeza longer than 6 months, the treating physician must provide proof that the patient is responding to treatment, defined as reduction in LDL-C levels.
HoFH is a rare genetic disease that causes extremely high levels of LDL-C. Atherosclerotic cardiovascular disease (ASCVD) occurs when LDL-C builds up inside the arteries, leading to hardening and narrowing of arteries and resulting in reduced blood flow. Severe outcomes of ASCVD because of HoFH may include heart attack, stroke, or death. HoFH is estimated to occur in 1 in every 250,000 people globally and affects approximately 80 people in Canada.
Statins and ezetimibe are the standard treatments for lowering cholesterol, but these alone may not help most patients with HoFH. Other options — including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors — are not publicly funded, which reduces the treatment options available to all patients, and while effective, the removal of LDL-C from the blood (LDL apheresis) is only temporary and time-consuming. There is a need for more treatments in HoFH that lower LDL-C, reduce the need for or frequency of LDL apheresis, and reduce cardiovascular morbidity and death.
Treatment with Evkeeza is expected to cost the public drug plans approximately $460,839 per year, assuming a patient weight of 70 kg.
The CADTH Canadian Drug Expert Committee (CDEC) recommends that evinacumab be reimbursed as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)–lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH), only if the conditions listed in Table 1 are met.
HoFH is a rare genetic disease in which atherosclerotic cardiovascular disease (ASCVD) occurs at a very young age, progressing aggressively throughout life, and can result in premature death. Although treatments are available, CDEC emphasized that substantial morbidity and mortality still exists, highlighting a significant unmet need for patients with HoFH. While there was insufficient evidence to evaluate the effect of evinacumab on the reduction in cardiovascular (CV) morbidity and mortality, CDEC recognized that reducing LDL-C levels is an important outcome in patients with HoFH, and there is a relationship between LDL-C levels and CV morbidity and mortality in this patient population.
One phase III, double-blind randomized controlled trial (RCT) (the ELIPSE trial; N = 65) demonstrated that, compared with placebo, evinacumab 15 mg/kg every 4 weeks resulted in added clinical benefit for patients aged 12 years and older with HoFH in reducing plasma LDL-C. In the ELIPSE trial, evinacumab resulted in a statistically significant and clinically meaningful percent reduction in LDL-C from baseline at 24-weeks compared to placebo (least squares mean difference [LSMD] = −49.0%; 95% confidence interval [CI], −65.0 to −33.1). In addition, evinacumab was associated with a clinically meaningful reduction from baseline in absolute LDL-C and apolipoprotein B (Apo B), and a clinically meaningful proportion of patients with a percent reduction in LDL-C of 30% or more. Results from 1 single-arm, open-label study (the CL-17100 trial; N = 20), which enrolled patients aged 5 to 11 years with HoFH, were consistent with those observed in the ELIPSE trial for the outcomes of percent and absolute change from baseline in LDL-C.
Patients identified a need for treatment options that reliably and consistently control LDL-C at normal or near-normal levels, reduce the frequency and need for apheresis, and reduce CV events. Based on the evidence reviewed, CDEC concluded that evinacumab meets the need of reducing LDL-C, but there was insufficient evidence to evaluate the effect of evinacumab on the reduction in the frequency of apheresis or CV morbidity and mortality.
Using the sponsor-submitted price for evinacumab and publicly listed prices for all other drug costs, the incremental cost-effectiveness ratio (ICER) for evinacumab was $8,392,585 per quality-adjusted life-year (QALY) gained, compared with standard of care. At this ICER, evinacumab is not cost-effective at a $50,000 per QALY willingness-to-pay threshold for patients aged 5 years and older with HoFH. A price reduction is required for evinacumab to be considered cost-effective at a $50,000 per QALY gained threshold.
Reimbursement Conditions and Reasons.
Familial hypercholesterolemia (FH) is a genetic disorder characterized by markedly elevated plasma levels of LDL-C from birth that persist throughout life and can lead to the early development of ASCVD. FH can be further subdivided into heterozygous FH (HeFH) and homozygous FH (HoFH) disease, with HoFH being the more severe and rare form of the disease. HoFH is characterized by profoundly elevated plasma levels of LDL-C from birth, putting HoFH patients at a significantly increased risk of early CV events (including myocardial infarction [MI], stroke, and heart failure), and if left untreated, patients with HoFH can be at risk of sudden cardiac death as early as childhood or adolescence.
Diagnosis of HoFH can be made based on clinical criteria or genetic confirmation, although historically, HoFH has been more commonly diagnosed based on clinical presentation, due to the lack of widespread availability of genetic testing in Canada. The Canadian Cardiovascular Society (CCS) Position Statement on FH lacks specific guidance for diagnostic differentiation between HeFH and HoFH; however, clinicians in Canada use the clinical diagnostic features of HoFH per the recently updated 2023 European Atherosclerosis Society (EAS) guidelines, which include untreated LDL-C levels greater than 10.0 mmol/L (400 mg/dL), or LDL-C greater than or equal to 8 mmol/L (300 mg/dL) while on conventional lipid-lowering therapies (LLTs). Additional clinical features include the presence of xanthomas before the age of 10 years, or the presence of HeFH in both parents. Genetic confirmation of diagnosis is based on the identification of biallelic pathogenic variants at the low-density lipoprotein receptor (LDLR), apolipoprotein B (Apo B), PCSK9, or low-density lipoprotein receptor adaptor protein 1 (LDLRAP1), or at least 2 such variants at different loci.
There are an estimated 145,000 patients with FH in Canada, although recent studies in unselected general populations suggest that HoFH may affect as many as 1 in 300,000 people, and may be higher in populations with a founder effect such as one that has been observed in French Canadians, with an estimated prevalence of 1 in 250,000. Overall, there are approximately 80 known cases of HoFH in Canada, and in 2022, there were 52 patients with confirmed HoFH enrolled in the Canadian HoFH Registry, with a majority (69%) found in Quebec, attributable predominantly to founder effects. Patients with HoFH are at a 100-fold elevated risk for MI compared to those without the condition. Untreated patients with HoFH who are LDLR-negative (i.e., who have a complete loss of LDL function) rarely survive beyond the second decade of life, while patients who are LDLR-defective (i.e., who have partial LDLR activity) have a better prognosis, although most develop clinically significant ASCVD by the age of 30 years if left untreated.
The overarching goal of therapy for HoFH is to lower LDL-C and, subsequently, the risk of ASCVD. The lowering of plasma cholesterol levels is known to reduce CV events, coronary heart disease mortality, and all-cause mortality. Recommended lifestyle modifications, as per the CCS guidelines on the diagnosis and treatment of dyslipidemias, include weight control, reducing the amount of fat intake to less than 30% of daily calories, consuming 10 g to 20 g of fibre per day, and increased physical activity. Additional lifestyle changes include smoking cessation and limiting alcohol intake. Statins are the primary pharmacological intervention to achieve control of LDL-C in patients with hypercholesterolemia. Most patients with hypercholesterolemia should be initiated on the MTD of high-intensity statins (atorvastatin or rosuvastatin), with the goal of lowering LDL-C by at least 50%. In cases of primary prevention, where the LDL goal is unmet through statin therapy alone, add-on ezetimibe or bile acid sequestrants (or both) is recommended, further reducing LDL-C by 10% to 40% (average 20%). If LDL goals are still not met, PCSK9 inhibitors (evolocumab) are available to patients meeting certain criteria as an adjunct treatment to diet, MTD statins and ezetimibe. However, given that traditional LLTs such as statins and PCSK9 inhibitors act by upregulating LDLR expression, they have little efficacy in HoFH patients and virtually no activity in those with 2 null LDLR alleles. Nearly all patients with HoFH will require extracorporeal LDL-C removal, particularly if the LDL-C levels remain greater than 5 mmol/L despite treatment, or if ASCVD is present. Either plasmapheresis or preferably LDL-C apheresis should be started as soon as technically feasible, usually before the age of 5 years and at least by the age of 8 years.
Evinacumab (Evkeeza) is a recombinant human monoclonal antibody that binds to and inhibits angiopoietin-like 3 (ANGPTL3), a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). Inhibition of ANGPTL3 via evinacumab lowers triglycerides and high-density lipoprotein cholesterol (HDL-C) by releasing LPL and EL. Evinacumab reduces LDL-C independent of LDLR by promoting very low-density lipoprotein (VLDL) processing and VLDL remnants clearance upstream of LDL formation through an EL-dependent mechanism.
Evinacumab has been approved by Health Canada as an adjunct to diet and other LDL-C–lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with HoFH. Evinacumab is a recombinant human monoclonal antibody, which specifically binds to and inhibits ANGPTL3. It is available as a 150 mg/mL concentrate for solution for infusion, and the dosage recommended in the product monograph is 15 mg/kg administered by IV infusion over 60 minutes every 4 weeks.
To make its recommendation, the committee considered the following information:
CADTH reviewed 1 joint patient input from CHPA and CORD. Information from respondents was gathered via an online survey that ran from April 12, 2023, to May 7, 2023, as well as individual interviews conducted with patients with HoFH and caregivers. All patients (N = 18) resided in Canada, mostly in Ontario (12 [66.7%]), with 3 (16.7%) each in British Columbia and Quebec. Regarding the impact of HoFH on patients, about 75% of respondents had experienced severe (very high) levels of LDL-C and 25% reported moderate levels of LDL-C. Around 50% of the respondents reported that they had experienced moderate or severe CV events, including atherosclerosis, stroke, atrial fibrillation, and/or cardiac infarction, and half of the patients had experienced severe chest pains or had xanthomas. Patients and caregivers highlighted that living with HoFH was associated with stress due to physical symptoms and the uncertainty or unpredictability of the future, with younger patients noting that HoFH impacted their education and social life, partly because of the time required for treatment. Patients expressed the need for treatment options that can reliably, consistently, and sustainably control LDL-C levels at normal or near-normal levels, allowing them to experience fewer spikes, reducing the frequency and need for apheresis, and reducing the risk of CV events. Patients with HoFH questioned the effectiveness of current treatment options (apheresis, statins, and other medications) in managing their LDL-C levels, highlighting the concerns of undergoing surgery in advance of or because of future CV events, further impacting their HRQoL and life expectancy. Of the 18 patients who provided input, 6 reported having access to or experience with evinacumab through a clinical trial, compassionate access program, or research study. Patients indicated that they were satisfied with evinacumab, as the treatment consistently lowered their LDL-C levels and improved their HRQoL through reduced frequency of apheresis, improvements in energy, and the ability to participate in social and family events and attend school. Additionally, there were no reports of serious adverse events (SAEs) following the use of evinacumab.
The information in this section is based on input received from a panel of 4 clinical specialists consulted by CADTH for the purpose of this review.
HoFH is a rare disease, and patients with HoFH are diagnosed based on standard, well-established clinical and genetic criteria, although genetic confirmation is not required. Patients present at an early age with extremely elevated LDL-C levels (untreated LDL-C greater than or equal to 10 mmol/L), as well as other clinical characteristics including the presence of xanthomas. The clinical experts noted that there are currently multiple established guidelines for the management of dyslipidemia, and highlighted the recent publication of the EAS Consensus Statement of HoFH. The experts noted that current guideline-recommended LDL-C thresholds are pragmatic and remain well above the acceptable level for patients without hypercholesterolemia. Per the current guidelines, the target LDL-C level for patients with HoFH is below 2.5 mmol/L; however, the experts agreed that this value is pragmatic and arbitrary, based on other treatments and clinical trial criteria.
The clinical experts highlighted that survival for HoFH patients has nearly doubled in a generation due to the LLTs available; however, they noted that repeated CV events — including MI, aortic valve stenosis, and aortic root disease — and the need for revascularization have increased. As such, the clinical experts emphasized that the main goal of treatment for patients with HoFH is to reduce LDL-C aggressively and safely over the longest term possible to prevent premature CV disease (CVD). In the pediatric population, the goal of LDL-C–lowering treatment is to prevent or delay ASCVD and obviate the need for or reduce apheresis. For adults, the goal of LDL-C–lowering treatment is to slow or halt ASCVD and potentially reverse it and its progression to clinically manifest CVD.
Most currently available pharmacological treatments only target the function of LDLR, rendering them less effective in HoFH, and they are more effective in patients with residual LDLR function, rather than “null” mutations where there is no functional LDLR. The clinical experts noted that once a patient is diagnosed, they are immediately put on the MTD of statins and ezetimibe therapy. In most cases, this combination is insufficient to meet the desired LDL-C targets. To further reduce LDL-C levels, PCSK9 inhibitors may be tried; however, the experts noted that, given the pathophysiology of HoFH and the mechanism of action of PCSK9 inhibitors, response may be limited although it should still be attempted. Often statins, ezetimibe, and PCSK9 inhibitors do not achieve sustained and significant reductions of LDL-C to levels below 2.5 mmol/L and/or a 50% lowering of LDL-C. If LDL-C levels are still above the goal, other treatment options — including lomitapide with or without extracorporeal removal of circulating LDL-C — may be attempted; however, these other treatment options have a notable impact on HRQoL as lomitapide is associated with the need for severe dietary restrictions, as well as adverse reactions and poor tolerability or compliance. In addition, extracorporeal removal of LDL-C, while effective, is extremely invasive, burdensome, and associated with a rebound period during which LDL-C levels rise to baseline, requiring recurrent and sustained treatment cycles. The experts highlighted the need for a drug that is safe and effective to lower baseline levels to a similar degree to that achieved with pheresis, without the same burden. The experts also noted that not all patients are able to access the full armamentarium of treatments available, and access to pheresis may be limited in Canada, with only 4 centres in Canada (Toronto, London, Québec City, and Edmonton). Plasmapheresis, which is more widely available, is considered a less optimal substitute for LDL apheresis.
The experts highlighted that evinacumab would likely be used as an add-on to MTD statins, ezetimibe, and/or PCSK9 inhibitors, preferentially with the hope of supplanting lomitapide and either delaying or reducing the frequency of pheresis.
The experts highlighted that the selection of patients most in need of intervention with evinacumab is not entirely based on disease characteristics but would be preferred in patients with an LDL greater than 2.5 mmol/L despite maximally tolerated therapy, and would be preferentially used in patients receiving or being considered for lomitapide or those on or being considered for apheresis, based on the poor risk-benefit profile of lomitapide and the burden of extracorporeal LDL-C removal. Per the clinical experts, patients most likely to benefit from treatment with evinacumab are those diagnosed with HoFH who have experienced limited or inadequate response to available LLTs. In addition to the treatments available, patients with ASCVD, aortic valve disease, or genetic documentation of 2 pathogenic variants represent subsets of high-risk patients for whom evinacumab might be considered. Regarding patients least suitable for treatment, the experts noted that there are no patients with HoFH that they would not consider for evinacumab, and regarding treatment history noted that it is highly unlikely that patients would be able to meet desirable LDL-C targets on conventional statin and ezetimibe therapy alone.
The clinical experts agreed that the most important outcome of treatment is the reduction of CV morbidity or mortality; however, they noted that LDL-C is the most reasonable surrogate outcome used by clinicians to avoid all downstream ASCVD complications. Additionally, the clinical experts noted that current clinical trials aim to address important outcomes that are used in clinical practice, and measuring event-driven outcomes is unreasonable in this population due to the rarity of the disease and the length of time before events accrue. Additionally, from a functional perspective, avoidance of pheresis options would be a measure of treatment success, although there are currently no data to demonstrate this potential benefit yet. Additionally, while the experts noted there are no data, they mentioned that patients’ disease should be stable on evinacumab for 6 months before attempting to reduce the frequency of or remove pheresis.
When deciding to discontinue treatment, the clinical experts agreed that treatment would be discontinued in patients who experience severe adverse events (AEs) including anaphylactic or infusion reactions that are unable to be managed. Additionally, the experts agreed that any new AEs that were identified could be cause for discontinuation, given the small sample size included in the trials for evinacumab. The experts noted that progression of atherosclerosis, major adverse cardiac events (MACEs), or lack of response to treatment may still occur with sustained treatment; however, the experts stated that this would not prompt discontinuation of treatment. While there is no strict definition for lack of response in this population, the experts highlighted that arbitrary LDL-C cut points would be chosen for determining an acceptable LDL-C reduction, although this would be contextual for each individual patient. However, the experts also emphasized that it would be inappropriate to discontinue or deny access to therapies that provide any safe lowering of LDL-C. For example, the experts noted that a treatment offering patients a 20% reduction in LDL-C might be below an arbitrary 30% cut-off, however, the experts agreed that they would not likely discontinue treatment and would not consider a 20% reduction in LDL-C a lack of efficacy.
Patients with HoFH are under the care of specialists with special qualifications in dyslipidemia (e.g., endocrinologists, cardiologists, and lipidologists), and treatment would occur within the specialist’s facilities or those accessible to the patient. Patients with HoFH are under the care of a lipid specialist, and are seen as often as every 3 months, and at minimum every 6 months. During pheresis therapy, lipid profiles are conducted before and after pheresis treatment; as such, LDL-C is routinely tracked. The experts noted that as an IV infusion, treatment necessitates an infusion-specific setting, as infusion reactions and flu-like reactions may occur. For patients receiving pheresis treatments, evinacumab would be easiest to administer where extracorporeal machines are located. The experts also noted that vascular access in children may pose a potential challenge. Given the dispersion of the population, the experts noted that comanagement with primary care physicians could be envisioned, and administration of evinacumab outside the specialist setting may be possible under the remote supervision of a specialist. The experts also highlighted that experience with evinacumab is limited; therefore, moving treatment into the community setting may be possible in the future although not likely to occur yet.
One clinician group, FH Canada, provided input for this review. Information from this group was gathered through the collective clinical experience of 7 clinical experts, published literature, and congress proceedings. Overall, the clinician group noted that there is an unmet need for equitably accessible therapies that safely and effectively treat HoFH patients. The clinician group highlighted that the current treatment options (statins, ezetimibe, and PCSK9 inhibitors, with or without plasmapheresis or apheresis), are inadequate in lowering LDL-C in patients with HoFH due to lack of efficacy and differences in mechanism of action (with statins, ezetimibe, and PCSK9 inhibitors), lack of tolerability (with lomitapide), and invasiveness (i.e., reduced HRQoL and disruption to patients’ and families’ daily lives [with apheresis and plasmapheresis]). Additionally, the clinician group highlighted the lack of availability of apheresis and plasmapheresis given that it is limited to major academic centres, resulting in additional travel burden, and creating inequities in the level of care of patients based on geographic location across Canada. Patients best suited for treatment with evinacumab, according to the clinician group, are those whose LDL-C levels do not meet the target levels with current treatments, or those with progressive CVD despite the use of current treatments. The clinician group indicated that evinacumab would likely be used as a fourth-line therapy after statins, ezetimibe, and PCSK9 inhibitors, and suggested that evinacumab may eliminate or reduce the need for plasmapheresis or apheresis and possibly lomitapide. In line with the clinical experts consulted by CADTH, the clinicians from FH Canada considered reduction in LDL-C levels to be the most important outcome of treatment. The clinician group cited a sustained reduction in LDL-C greater than 20% to 30% as a meaningful response to treatment. An additional important outcome for assessing response to treatment included reduction in the frequency of apheresis or plasmapheresis. The clinician group noted that intolerable side effects would be the primary factor when deciding to discontinue treatment.
Input was obtained from the drug programs that participate in the CADTH reimbursement review process. The clinical experts consulted by CADTH provided advice on the potential implementation issues raised by the drug programs.
Responses to Questions From the Drug Programs.
Two studies — the CL-1629 (ELIPSE) trial and CL-17100 trial — were included in this review. The ELIPSE trial was a pivotal, phase III, double-blind, randomized placebo-controlled trial designed to evaluate the efficacy and safety of evinacumab versus placebo in pediatric and adult patients with HoFH. A total of 65 patients were randomized 2:1 to evinacumab 15 mg/kg every 4 weeks or matching placebo. Three patients were enrolled from Canadian investigative sites. The primary outcome of the ELIPSE trial was the change from baseline in LDL-C at week 24. Secondary outcomes included the percent change from baseline to week 24 in Apo B, non-HDL-C, and total cholesterol; the proportion of patients with greater than or equal to 30% and greater than or equal to 50% reduction in LDL-C at week 24; the absolute change in LDL-C from baseline to week 24; the proportion of patients with LDL-C less than 100 mg/dL (2.59 mmol/L) at week 24; and the proportion of patients who meet EU or US apheresis eligibility criteria at week 24.
The CL-17100 study, which was considered a supportive trial for this review, included 3 parts (parts A, B, and C). Part A was a phase Ib, single-arm, single-dose, pharmacokinetic and pharmacodynamic study consisting of a 16-week, open-label treatment period; it enrolled 6 patients with HoFH. Only parts B and C were of interest to this review. Part B was a 24-week, phase III, single-arm, open-label study to assess the efficacy and safety of evinacumab in pediatric patients aged 5 to 11 years with HoFH. A total of 14 patients were enrolled into part B, and no patients from part A were enrolled into part B. Upon completion of part B, all patients continued into Part C. Part C is an ongoing extension period consisting of the 20 patients who completed part A (N = 6) and part B (N = 14). Part C consisted of a 48-week treatment period and a 24-week follow-up period after the last dose of evinacumab. The final dose in part C was the same as the dose in part B (15 mg/kg IV every 4 weeks). The data cut-offs for parts B and C were January 31, 2022, and |||| || ||||, respectively. The primary outcomes of parts B and C were identical to the ELIPSE trial, with secondary outcomes of percent change from baseline to week 24 in Apo B, non-HDL-C, and total cholesterol; the proportion of patients with greater than or equal to 50% reduction in LDL-C at week 24; the absolute change in LDL-C from baseline to week 24; and the proportion of patients with LDL-C less than 100 mg/dL (2.59 mmol/L) at week 24.
In the ELIPSE trial, there was a difference between evinacumab and placebo groups in terms of age at baseline, with a mean age of 44.3 years (standard deviation [SD] = 16.8) in the evinacumab group compared to 36.7 years (SD = 11.52) in the placebo group. Only 1 patient in each treatment group was younger than 18 years. In line with the difference in age, there was also a difference in mean time from diagnosis of HoFH, with the mean time from diagnosis of 16.15 years (SD = 14.562) in the evinacumab group compared to 10.65 years (SD = 12.537) in the placebo group. A total of 48.8% of patients had homozygous LDLR mutations in the evinacumab group compared to 31.8% in the placebo group, while fewer patients in the evinacumab group had compound heterozygous mutations compared to those in the placebo group (27.9% versus 36.4%). Most patients had received at least 3 LLTs (69.8% versus 50.0%), consisting mostly of the combination of statins plus ezetimibe and a PCSK9 inhibitor (48.8% versus 36.4%). More patients in the evinacumab group had received lomitapide than in the placebo group (25.6% versus 13.6%). Lipid parameters were comparable across treatment groups (LDL-C, 259.5 mg/dL versus 246.5 mg/dL; Apo B, 169.1 mg/dL versus 175.9 mg/dL; non-HDL-C, 281.9 mg/dL versus 269.9 mg/dL; and total cholesterol, 325.6 mg/dL versus 315.9 mg/dL).
The CL-17100 study was conducted in pediatric patients with HoFH aged 5 to 11 years. The mean age of patients enrolled in part B of the CL-17100 study was 9.1 years (SD = 1.94). Most patients (71.4%) had compound heterozygous mutations, and 50% of patients had had prior apheresis at baseline. Nearly all patients had been treated with statins (85.7%) and ezetimibe (92.9%), and only 2 patients (14.3%) had received lomitapide. Lipid parameters at baseline were similar to the ELIPSE trial, with LDL-C of 263.7 mg/dL, Apo B of 168.2 mg/dL, non-HDL-C of 282.2 mg/dL, and total cholesterol of 315.5 mg/dL.
During the 24-week double-blind period of the ELIPSE trial, the least squares mean (LSM) percent change from baseline with evinacumab was −47.1% (standard error [SE] = 4.6), compared to 1.9% (SE = 6.5) with placebo. In the double-blind treatment period, the LSMD between evinacumab and placebo in percent change in LDL-C from baseline at 24 weeks was −49.0% (95% confidence interval [CI], −65.0 to −33.1), favouring evinacumab. During the open-label treatment period of ELIPSE, the overall percent reduction in LDL-C at 48 weeks in the open-label treatment period was −46.31% |||| ||||||. Results of sensitivity analyses and subgroup analyses by background LLT, apheresis status, baseline LDL-C level, and HoFH genotype were consistent with the primary analysis, in favour of evinacumab.
In the CL-17100 study, results for LSM change from baseline in LDL-C with evinacumab from part B and the pooled part B and C were consistent with the double-blind period of the ELIPSE trial, with percent reductions of −48.32% |||| ||||||| ||| ||||||| |||| ||||||| at 24 weeks, respectively.
The absolute change from baseline in LDL-C during the 24-week double-blind treatment period of ELIPSE was −134.7 mg/dL (SE = 12.4) in the evinacumab group compared to −2.6 mg/dL (SE = 17.6) in the placebo group, favouring evinacumab (LSMD = −132.1 mg/dL [95% CI, −175.3 to −88.9]; P < 0.0001). In the open-label treatment period, ||| |||||||| |||||| |||| |||||||| || ||||| || || ||||| ||| |||||| ||||| |||| |||||||.
In part B of the CL-17100 study, the LS mean absolute change from baseline in LDL-C was −131.9 mg/dL (SD, 30.0).
In the 24-week double-blind treatment period of the ELIPSE trial, 83.7% of patients in the evinacumab group and 18.2% of patients in the placebo group experienced a greater than or equal to 30% reduction in LDL-C, favouring evinacumab (odds ratio [OR] = 25.2 [95% CI, 5.7 to 110.5]; P < 0.0001).
The proportion of patients with a greater than or equal to 30% reduction in calculated LDL-C at week 24 was not evaluated in the open-label treatment period of the ELIPSE trial or in the CL-17100 study.
In the ELIPSE trial, during the 24-week double-blind treatment period, the LSM percent change from baseline in Apo B was −41.4% (SE = 3.3) with evinacumab compared to −4.5% (SE = 4.8) with placebo, favouring evinacumab (LSMD = −36.9% [95% CI, −48.6 to −25.2]). The overall percent reduction in LDL-C at 48 weeks in the open-label treatment period was ||||||| |||| |||||||.
In the CL-17100 study, the LSM change from baseline in Apo B with evinacumab from part B ||| ||| |||||| |||| |||| | was −41.32% |||| ||||||||||||||||| |||| |||||||| |||||||||||||
The proportion of patients with LDL-C less than 100 mg/dL (2.59 mmol/L) at 24 weeks was 46.5% in the evinacumab group compared to 22.7% in the placebo group (OR = 5.7 [95% CI, 1.3 to 24.9]; P = 0.0203).
The proportion of patients with LDL-C less than 100 mg/dL was not evaluated in the open-label treatment period of the ELIPSE trial or in the CL-17100 study.
In the ELIPSE trial, the proportion of patients with LDL-C less than 70 mg/dL (1.81 mmol/L) at 24 weeks was 27.9% in the evinacumab group compared to 4.5% in the placebo group (OR = 20.9 [95% CI, 1.6 to 276.8]; P = 0.0209).
The proportion of patients with LDL-C less than 70 mg/dL was not evaluated in the open-label treatment period of the ELIPSE trial or in the CL-17100 study.
In the ELIPSE trial, the proportion of patients who met US apheresis eligibility criteria at 24 weeks was 7.0% in the evinacumab group compared to 22.7% in the placebo group (OR = 0.1 [95% CI, 0.0 to 1.3]; P = 0.0845). Statistical hypothesis testing was terminated at this end point in the ELIPSE trial because statistical significance was not reached.
The proportion of patients who met US apheresis eligibility criteria was not evaluated in the open-label treatment period of the ELIPSE trial or in the CL-17100 study.
In the ELIPSE trial, the proportion of patients who met EU apheresis eligibility criteria at 24 weeks was 32.6% in the evinacumab group compared to 77.3% in the placebo group (OR = 0.1 [95% CI, 0.0 to 0.3]).
The proportion of patients who met EU apheresis eligibility criteria was not evaluated in the open-label treatment period of the ELIPSE trial or in the CL-17100 study.
In the ELIPSE trial, the mean EQ-5D utility score at 24 weeks was |||||| |||||| |||| ||||| for evinacumab and |||||| |||||| |||| ||||| for placebo, representing a mean change from baseline of ||||||| |||||| |||| ||||| with evinacumab, and ||||||| |||||| |||| ||||| with placebo.
Quality of life was not evaluated in the open-label treatment period of the ELIPSE trial or in the CL-17100 study.
All-cause and CV-related mortality were not evaluated in the ELIPSE or CL-17100 studies.
CV-related morbidity outcomes, such as the incidence of resuscitated cardiac arrest, nonfatal MI, and stroke, were not evaluated in the ELIPSE or CL-17100 studies.
In the ELIPSE trial, the incidence of treatment-emergent adverse events (TEAEs) was lower for patients treated with evinacumab compared to placebo during the double-blind treatment period (65.9% versus 81.0%). In the open-label treatment period of the ELIPSE trial, the incidence of TEAEs for evinacumab ||| |||||| |||| ||| |||||||||||| ||||||||| |||||| |||||||. The most common TEAEs in patients treated with evinacumab versus placebo included nasopharyngitis (15.9% versus 23.8%) and influenza-like illness (11.4% versus 0.0%). In the open-label treatment period, the most frequently reported TEAEs |||||||| ||||||||||||||| ||| |||||||| ||||| |||||. SAEs in the ELIPSE trial occurred in 2 (4.5%) patients in the evinacumab group and consisted of urosepsis (1 |||||||) and attempted suicide (1 |||||||). There were no SAEs in the placebo group. There were no withdrawals due to AEs or deaths reported during the ELIPSE study. In terms of notable harms, 4 patients (9.1%) in the evinacumab group and 3 patients (14.3%) in the placebo group experienced allergic events, and 3 patients in the evinacumab group (6.8%) and 1 patient in the placebo group (4.8%) experienced infusion-related reactions (IRRs) during the double-blind treatment period of ELIPSE.
In the CL-17100 study, |||||| ||| |||||||| ||||||| |||| |||||||||| ||||||||||| || ||||| ||||| |||||||| ||| |||| |||||||| |||||||||| ||| || ||||||||| |||| |||||||| |||||||| |||||||| ||| ||||||||||||||| |||||||| One patient (5.0%) experienced an SAE of tonsillitis. There were no withdrawals due to AEs or deaths reported during the CL-17100 study. ||||||| ||||| || ||||||| |||||||| |||||| |||||||| || |||||||| ||||||||| ||| || |||||||| ||| ||||.
The ELIPSE trial was a first-in-class, phase III, placebo-controlled RCT that included both double-blind and open-label treatment periods. Appropriate methods for randomization (using interactive response technology), treatment allocation (stratified by apheresis treatment and by region), and maintenance of blinding to treatment assignment were used, reducing selection, performance, and detection biases. The CL-17100 study was an open-label, single-arm study of evinacumab in patients with HoFH aged 5 to 11 years. The choice to conduct a single-arm trial in the younger population was justified considering the rarity of the indication and the age of the participants; however, the noncomparative nature negates the ability to draw definitive conclusions on the effectiveness of evinacumab due to the small sample size and chronic progression of HoFH. As such, the strength and interpretability of the results for this group of patients is limited. Dropouts and missing data in the ELIPSE and CL-17100 studies were low. The primary end point of the ELIPSE trial used a mixed-effect model with repeated measures to account for missing data under the missing at random assumption, which may not hold in this setting and lead to overconfidence in the effect size. The sensitivity analyses used a pattern mixture model to account for nonignorable missingness, although overall, missing data were low and unlikely to impact the results. Acceptable methods to account for multiplicity were used in the ELIPSE trial. The primary and key secondary end points were controlled for multiplicity at the 0.05 level using a hierarchical testing sequence. However, at the end point of proportion of patients who met US apheresis eligibility criteria, statistical significance was not achieved; thus, the multiple testing procedure failed, and all subsequent outcomes (the proportion of patients with LDL-C less than 100 mg/dL, and the proportion of patients who meet EU apheresis eligibility criteria) should only be viewed as supportive. While they generally supported the primary analysis, subgroup analyses in the ELIPSE and CL-17100 trials were not statistically powered to detect within-group or between-group differences; therefore, the results from the subgroup analyses should be interpreted as supportive evidence only for the overall effect of evinacumab.
The clinical experts consulted by CADTH indicated that the inclusion and exclusion criteria for the ELIPSE and CL-17100 studies were appropriate, although they highlighted that genetic confirmation of HoFH is not always conducted. Both the ELIPSE and CL-17100 studies were multinational studies; however, the ELIPSE trial was the only study to enrol patients in Canada (N = 3), although given the low number of patients in Canada enrolled, generalizability based on geography cannot be assumed. HoFH is a rare disease, which expectedly resulted in the small sample sizes for the ELIPSE and CL-17100 studies. In total, the ELIPSE trial included 65 patients with HoFH, and the CL-17100 trial included 20 patients. The clinical experts consulted by CADTH noted that, in their experience, the populations included in the trials were generally in line with clinical practice in Canada with regard to age of patients and LDL-C levels at baseline. The chosen comparator of placebo in the ELIPSE study was appropriate and aligns with the recommended standard of care guidelines for HoFH in Canada, for which the experts noted that standard of care consists of MTD statins, ezetimibe, and a PCSK9 inhibitor. The clinical experts consulted by CADTH noted that the proportion of patients receiving various LLTs was in line with the general patient population with HoFH, although the proportion of patients in the ELIPSE trial receiving PCSK9 inhibitors was higher than in Canadian clinical practice, considering the difficulty accessing PCSK9 inhibitors in Canada. There were minor differences in lomitapide use at baseline, with only 11 patients (25.6%) in the evinacumab group and 3 patients (13.6%) in the placebo group receiving lomitapide, although this was potentially related to the rarity of the disease and study design, as differences in patients may be more noticeable in studies with small sample sizes. The outcomes used to inform the efficacy of evinacumab in the ELIPSE and CL-17100 studies were chosen based on validated laboratory assessments of lipids and are considered widely accepted surrogates for clinically relevant CV outcomes and important in guiding treatment decisions in Canadian clinical practice in patients with HoFH. In addition to the well-established lowering of LDL-C, the most valuable outcomes to patients with HoFH included the reduction in the risk of CV events and reducing the need for apheresis. The included studies were not designed to assess important CV-related outcomes, including reductions in MACE and all-cause and CV-related mortality, although the clinical experts consulted by CADTH noted that measuring event-driven outcomes like these is difficult in HoFH, due to the rarity of the disease. Additionally, impact on HRQoL was an exploratory outcome of the ELIPSE trial and was not evaluated in the CL-17100 study. The clinical experts consulted by CADTH noted that reduction in the burden of apheresis requirements is believed to impact patients’ HRQoL; however, the measurement of this in the available evidence was not captured. The clinical experts consulted by CADTH emphasized that the duration of the ELIPSE and CL-17100 studies (24 weeks) was considered appropriate for assessing lipid-related outcomes given that the effects on lipids are rapidly seen; however, they noted that the 24-week duration of the included studies was insufficient to determine the impact of evinacumab on CV-related morbidity and mortality, and HRQoL.
For pivotal studies and RCTs identified in the sponsor’s systematic review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of the evidence for outcomes considered most relevant to inform CADTH’s expert committee deliberations, and a final certainty rating was determined as outlined by the GRADE Working Group. Following the GRADE approach, evidence from RCTs started as high-certainty evidence and could be rated down for concerns related to study limitations (which refer to internal validity or risk of bias), inconsistency across studies, indirectness, imprecision of effects, and publication bias.
The selection of outcomes for GRADE assessment was based on the sponsor’s Summary of Clinical Evidence, consultation with clinical experts, and input received from patient and clinician groups and public drug plans. The following list of outcomes was finalized in consultation with expert committee members: reduction in LDL-C levels (percent change from baseline in LDL-C at 24 weeks, absolute change in LDL-C at 24 weeks, proportion of patients with ≥ 30% reduction in LDL-C at 24 weeks, proportion of patients who meet US apheresis eligibility criteria at 24 weeks, proportion of patients with LDL-C < 100 mg/dL [2.59 mmol/L] at 24 weeks, proportion of patients who meet EU apheresis eligibility criteria at 24 weeks, proportion of patients with LDL-C < 70 mg/dL [1.81 mmol/L] at 24 weeks), reduction in other lipid parameters (percent change in Apo B from baseline at 24 weeks), and improved HRQoL (change from baseline in EQ-5D utility score at 24 weeks).
When possible, certainty was rated in the context of the presence of an important (nontrivial) treatment effect; if this was not possible, certainty was rated in the context of the presence of any treatment effect (i.e., the clinical importance is unclear). In all cases, the target of the certainty of evidence assessment was based on the point estimate and where it was located relative to the threshold for a clinically important effect (when a threshold was available) or to the null. The target of the certainty of evidence assessment was the presence of a clinically important reduction of LDL-C (percent and absolute change in LDL-C) on thresholds informed from treatment guidelines and clinical expert opinion. Other targets for the certainty of evidence assessment were the presence or absence of any (non-null) effect for the proportion of patients achieving global lipid targets (i.e., percent change in Apo B, proportion of patients experiencing a 30% reduction in LDL-C, proportion of patients reaching LDL-C levels of 100 mg/dL or 70 mg/dL or less, the proportion of patients meeting US or EU apheresis criteria, and HRQoL measured by the EQ-5D).
Table 3 summarizes the detailed GRADE summary of findings for evinacumab versus placebo for outcomes in the pivotal ELIPSE trial of adolescent and adult patients with HoFH, while Table 4 summarizes the narrative GRADE summary of findings for evinacumab in the pediatric population of the CL-17100 trial and outcomes from the ELIPSE trial that were unable to be populated in the detailed summary of findings table.
Detailed Summary of Findings for Evinacumab vs. Placebo for Adolescent and Adult Patients With HoFH (ELIPSE Trial).
Narrative Summary of Findings for Evinacumab for Pediatric Patients With HoFH (CL-17100 Study).
The CL-1719 study was a key long-term extension study submitted by the sponsor. The CL-1719 study is an ongoing long-term extension study evaluating the safety, tolerability, and efficacy of evinacumab in patients with HoFH, some of whom had previously participated in an evinacumab study (continued evinacumab) and some who were naive to evinacumab (new evinacumab). All patients received 15mg/kg of evinacumab intravenously, every 4 weeks, for 24 months. The study consisted of a run-in phase, a screening phase, a treatment period, and a 24-week follow-up period. ||||| |||||||| |||||| |||| |||||| || || ||||||||||||| ||||||| || ||| ||||||| |||| ||||||| |||||| ||| |||||| ||| |||||||| ||| |||| |||||||| || ||| ||||| |||||||||| ||||||||||| || ||||| ||| |||||||||| |||||||||||| || |||||||| ||||||| ||| ||||||||| ||| ||||||||| ||||||| || |||||||| ||||||| |||| ||||||| || ||| ||||||||| ||||||| ||| || |||||||| ||||||| ||| ||||||||||||| ||| |||| ||| ||| |||| |||||| || ||||||| |||||||||| |||||||| ||| |||| ||||||||.
|||||||||| || ||||| |||||||||| |||||||| ||||| || ||| ||||||||| |||||| || ||| ||||| |||||||||| |||| |||||||||| |||| ||||||||||| |||||||||| ||||||||| || || || || ||||| ||| ||||| ||||| ||||||| |||||| |||| |||||||| || |||| ||| ||| ||||| ||| ||||||| ||| ||| ||||||||||||||| |||| |||||||||| || ||||||||||| |||||||| || ||||| ||||| ||| || ||| ||||| |||||||| |||||||||||| || ||| |||||||| ||| ||||||||||| || |||||||| ||||||| || |||||||||| ||||||||| ||| |||||||| |||||||| |||| ||| ||||||||||||| |||||||||| |||||| |||||| ||||||||||| |||| |||||||| || ||||| ||| ||||| ||||| |||||||||| || |||||||||| |||||||||| |||| |||||||||| |||| ||| ||||| ||||||||||| ||||||||| |||| |||||||||| |||||||| || |||||||||| |||||||||| || |||| ||||||| |||||| |||| |||||||| ||| |||||||||| ||||| |||||||||| ||| ||||||||||| || |||| || || |||| |||||| |||| |||| |||||||||| ||| || || || ||||| ||||| ||||||| |||||| |||| |||||||| || |||| || ||| ||||| ||| |||||||| ||| ||| |||||||||
|||| |||||||| ||||||||||| || ||||| ||| |||||||||||||||||| ||||||| ||||| ||||||| || || || ||||||| |||||||| || ||| |||||||||| ||||| |||||| || || || ||||||| || ||| |||||||||| |||||||||| |||||| ||| || || ||| ||||||| || ||| ||||| ||||||||||| ||| |||| |||||||||| |||||||| ||||| ||| ||| ||||| |||||||||| |||| |||||||||||||||| ||||||||| ||||||||| |||| |||||||| ||||||||||| |||||||| |||||||||| |||| ||||| ||| ||||||| ||| |||| ||||||| || ||| |||||||||| |||||||||| ||| ||||||| || ||| ||||| ||||||||||| |||||| |||||||| ||||||||||| || ||||| |||||| ||||||||||| |||||||| ||||||| || ||| ||||| |||||||||| ||||||||||| ||||||| |||||| || ||| |||||||||| ||||||||||| |||||||| |||||| ||||||||||| |||||||| ||||| ||||| |||||||| ||| |||||||||| ||||| ||||||| || ||||||||||||||| || ||||| ||||| ||| |||||||| || ||| ||||| |||||||||| ||||||||||| ||||||||||||||| ||||| ||||||||| || ||||| |||| |||| |||||||||| ||||||||| || ||||| ||||| ||||| |||| || |||||| |||||||| || ||| |||||||||| |||||||||||
The lack of an internal comparator limits the interpretation of the treatment effect observed in the CL-1719 trial, as it is uncertain whether the magnitude of the effect observed for evinacumab as an adjunct to background LLT in patients continuing with evinacumab and new patients is attributed to evinacumab, due to variations in patient health status (continuing and new patients enrolled), residual effects from the use of evinacumab (for patients entering study from an evinacumab study, the impact of ongoing treatments on the effect of evinacumab efficacy), or other unidentified prognostic factors. The single-arm design does not allow for the differentiation of the symptoms of underlying HoFH from treatment-related AEs.
There were no established hypothesis tests and clear thresholds for the secondary variables assessed in the trial. A lack of hypothesis testing against clear thresholds reduces the internal validity of the efficacy findings as it introduces bias in the interpretation of the findings. The open-label design may have also introduced bias in the assessment of subjective outcomes such as the reporting of AEs. Missing data and the lack of methods to account for missing data in the analysis may have impacted the internal validity of the results. ||||| |||| ||||||||||||| || |||| ||||||||||| |||||||| |||||||| || ||||| ||||||||| |||||| ||||| |||| |||||||||| || ||||||| || |||| || ||||||| ||||.
The CL-1719 study enrolled | |||||||| based in Canada, although it was unclear if the results were generalizable to patients in Canada due to the small sample size and study design. Outcomes investigated were appropriate and reflective of current clinical practice. Follow-up duration was considered appropriate and more reflective of real-world practice. Concomitant medication and background LLT reported among patients |||| || |||| |||| ||||| |||||||| || ||| |||||| ||| ||||||||| |||||. These concomitant medications were also reflective of current clinical practice.
No direct evidence comparing evinacumab to relevant comparators was available, and to support the pharmacoeconomic model for evinacumab, the sponsor submitted an indirect treatment comparison (ITC) that aimed to estimate the relative effect of evinacumab compared with relevant comparator treatments for adult and adolescent patients (aged 12 years and older) with HoFH to estimate the relative efficacy, safety, and tolerability of evinacumab compared with lomitapide, ezetimibe, evolocumab, and LDL apheresis.
The sponsor-submitted ITC first conducted a systematic literature review (SLR) to identify existing studies conducted in patients with HoFH. Patient-level data from the evinacumab and placebo arms of the ELIPSE trial were compared to aggregate data from the identified trials using Bucher ITCs and matching adjusted indirect comparison (MAIC) methods for the outcomes of percent reduction in LDL-C, proportion of patients with 50% reduction in LDL-C, proportion of patients who experienced any SAEs, and proportion of patients discontinuing the study due to any cause.
||| ||| |||||||||| || ||||||| ||||||||| |||| || |||||| ||||||| |||||| || ||||||||||| |||||||| ||| ||||||||| || ||| ||||| ||||||| |||| |||||||| ||| ||||||||||||| ||||| || ||||| ||||||| ||||||||||| ||||||||| |||||||| ||||||||||||||| ||| |||||||||||| || |||||||| ||||| ||||||||| |||||||||| || |||||||||||||| |||||||| |||| ||| ||| ||||||| || |||| ||||| |||| || |||| ||||| ||| ||||| || |||| |||||| || |||| || ||| |||||| ||||| |||| |||||||||| ||| ||||||||| || ||| ||||| ||| |||||| || ||||||||||||| ||||||| ||| ||| |||||||||| ||||| |||||| ||| ||||||||| |||| ||| |||||||||| |||| |||||| ||| ||| |||||||||| |||| |||| || |||| |||| ||| |||| ||||||||| ||| ||| |||||||| || ||||||| |||||| |||| |||||||| || ||||| || ||||||||| ||||||| |||||||||||| |||| |||||||||| ||| |||||||| |||| |||||||||| ||| ||||||| |||||| |||| |||||||| || ||||| ||||| |||||||||| ||||| ||||||| |||| ||| |||||| || |||||||| ||| ||| ||||| || |||||| |||||||||||| || |||||| || |||| |||| |||||||||||| ||| |||||| || ||||| || |||| |||| |||||||||||| ||||| ||||||||||| ||||| |||| || |||||||||| ||||||| |||||||| |||||||| |||||||||||||||| |||||| ||| ||| ||| |||||||||| ||| |||| ||| |||||||| || ||| |||||||||| |||| ||||||||||| ||| |||| || ||| |||||||||| |||| |||||||||| ||||||| || ||| |||| ||| ||| || || ||||||| |||||| |||| |||||||| || ||||| ||||||||| |||| ||||| ||| || |||||||||| ||||||| |||||||||| ||| |||||||||| ||||| |||||||||| |||| ||||| |||| ||| |||||| || |||||||| |||||| |||||||||| ||| |||||||| |||| ||||||||| |||| ||||||| |||| ||| |||||| || ||||||||| ||| ||| ||||||||| || |||||| ||||| ||| || |||||||||| ||||||| |||||||||| ||| |||||||||| ||||| |||||||||| ||||||||| |||| ||||| |||| |||| ||| ||||| ||||||.
The feasibility of conducting an ITC and subsequent analyses were informed by an SLR; however, no information was provided on the SLR methods with regard to the databases searched, the method of study selection or data extraction (i.e., duplicate reviewers), or quality assessment; thus, CADTH is unable to comment on whether appropriate methods were taken to identify studies for the inclusion in the ITCs. Two types of ITC were conducted: a MAIC and a Bucher ITC. Bucher ITCs were used for the comparison of evinacumab to evolocumab based on the connection of the studies via a placebo arm, |||||| ||| ||||||| ||| ||| |||||||| |||||||||| || || || ||||||||||| |||||||||| || |||||||||| ||||| || ||| |||| || ||||||||| |||| ||| |||||| |||||||||| ||| ||||||| ||| ||||||| ||| |||| |||||||| ||||||| ||| ||||| |||| ||||||||| ||| ||| ||||||||||| || ||||||||| ||| ||||||||||| ||| ||| ||||| |||||||||| || |||||||| ||| ||||| || ||| |||||||| ||| || |||||||| |||||||||| ||||| || |||||| |||| || |||||| |||| ||||||| ||||| |||| ||||||||| ||| ||||||||| || ||||| |||||||||| |||| ||| |||||||| ||| |||||||||| |||||||||||||| || ||||| |||||||||| ||| |||| |||||||| || |||| || ||| ||||||||| || ||||.
The clinical experts consulted by CADTH could not confirm or refute that the prognostic factors and treatment effect modifiers consisting of |||| |||||||| || |||| |||||||| |||||| ||| |||| |||||||| |||||| ||||||||||||||||||| || ||||||||| were the only relevant variables in this disease. The key limitation of the unanchored MAICs, which is a limitation inherent to all unanchored MAICs, is that the assumption that all effect modifiers and prognostic factors are accounted for in the model is unlikely met.
||| |||||| || ||||||| || |||||||||| |||| ||| ||||||||| || ||| |||| || ||||||| |||||||||| |||||| |||||||| |||||||| ||||| |||| ||||||||| ||||||||||| || ||| ||||| ||||||| ||||| ||| |||||| ||||| |||||||||||| ||| |||| || ||||||| |||||||||| ||| || || |||||| || ||| |||||||||| ||||||| |||| ||||| ||| ||||||| || |||| |||||| |||||||||| ||||| ||| |||||||| || |||||||||| |||||||| |||| ||||| |||||||||| || ||||| ||||| |||| |||| ||||||||||| || ||| |||||| |||| ||||||| || |||||||||| ||||||||||||||| |||| ||| |||||| ||| ||||||||||||| || ||| |||||||| ||||||| ||| ||||||||| || ||| |||||||||| || |||||||| |||| ||| || ||||||||| ||| |||||||||| || |||||||| ||||||||| ||||||||| || ||||||||| ||||||||||| || |||| |||||||| |||||| |||||| |||||||||||| ||| ||||||| ||||||||||| || ||||| |||||||||| ||||||||| |||||| ||| || ||| |||||||||| ||||||||| |||||||||| ||| |||||||||| ||||||| ||| ||||||||| |||||| |||||||||| ||| ||||||||| ||||||||| |||||| |||| ||||| ||| ||| |||||||||| ||||| ||| ||||||||| ||| ||| ||| ||| ||| ||||||||||| ||| |||||||||| ||| |||||||||| ||||||||||||| |||| || |||||| || ||| |||||||||||| ||||||||||||| |||||| ||||||| ||| ||| |||||| ||| ||||||||| ||||||||| || ||| |||| |||||||||| ||||| ||||||||| ||| ||||||||||| || ||| |||||||| || ||| ||||||| || ||| |||||||||| ||||||| ||| ||||||||| |||||| |||||||||| ||| |||| ||| ||||||||| ||| |||||| || |||| || || |||||||||| |||| |||||| || || |||||||||||| |||||||| ||||| ||| ||||||||||| |||| || |||||| |||| ||||| |||||||||| ||| ||||||| ||| ||| || ||||||||||||| || ||| |||||||| |||| |||||||||||
The outcomes evaluated in the ITCs are relevant to the clinical management of HoFH. The sponsor conducted a Bucher ITC between evinacumab and evolocumab for the outcome of change from baseline in LDL-C, although no formal statistical analyses or adjustments were conducted; therefore, the results of this analysis should be interpreted with caution. MAICs were conducted for the outcomes of percent change from baseline in LDL-C and 50% reduction in LDL-C. Additional naive ITCs were conducted for safety outcomes including SAEs and proportion of patients discontinuing the studies due to any cause| |||||||| ||||||||||| ||||| |||||||| |||| |||| |||||||||||| || |||||||||| ||||| || ||||| || ||| ||||||||||| ||||||| ||||| ||||||||||| ||||| ||| || |||||||| || |||||||||| ||| |||||||||| |||| |||||||||| ||| ||| ||||||| || ||||||| |||||| |||| |||||||| || |||||| ||| |||||||||| ||| |||||||| |||| |||||||||; however, in all cases, 95% CIs were wide, suggesting notable imprecision in comparative efficacy estimates.
The study by Stefanutti et al. (2022) assessed the long-term efficacy and safety of evinacumab in a cohort of patients with HoFH who were on and off background LDL apheresis, including other LLTs, in a real-world setting. Patients received evinacumab 15 mg/kg every 4 weeks for a duration of 24 months.
The mean percent reductions from baseline following the use of evinacumab and LDL apheresis treatment in LDL-C were −54.4%, −48.9%, −49.4%, and −46.8%, respectively, at 6, 12, 18, and 24 months (P < 0.001 for all compared with baseline). One patient discontinued LLT for hospitalization. Four patients experienced an LDL-C reduction of 50% or more, with 2 patients having on-treatment LDL-C levels less than 2.5 mmol/L (97 mg/dL).
The LDL-C–lowering effect of evinacumab with or without background LDL apheresis treatment was greater than with LDL apheresis alone (i.e., without evinacumab treatment). With LDL apheresis alone, time-average LDL-C was reduced by 27.2% in the 6 patients who received LDL apheresis during the normal course of their therapy before initiation of evinacumab treatment.
There were no discontinuations due to severe AEs reported following the use of evinacumab. There were also no CV events observed during the 24-month follow-up and subsequent compassionate extension period (12 months) with evinacumab. There were no reports of symptoms related to common AEs (pharyngitis, nasal congestion, myalgia, diarrhea, and arthralgia). Overall, plasma aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine kinase concentrations for individual patients with HoFH remained stable with treatment with evinacumab.
The lack of comparator and the open-label design of the prospective cohort were the main limitations of the study. There was no control group for comparison; thus, the benefit observed cannot be attributed to treatment with evinacumab. The sample size was considered too small to assess the magnitude of effects, and no sample size calculations were provided. There was little information provided related to the eligibility criteria of patients included in the study. There is a risk of detection bias for subjective outcome measurements such as AEs reporting due to the open-label nature of the study, given that patients and providers were aware of the treatment. The study duration (24 months) was considered long enough to assess the beneficial effects of evinacumab in the patient population. No HRQoL data were presented. It is uncertain whether evinacumab impacted patient outcomes in the real-world setting.
There is limited generalizability in terms of genetic confirmation of HoFH diagnosis. A clinical diagnosis criterion was not used in the study, which may not be reflective of Canadian practice guidelines. It was unclear what background LLTs were used alongside LDL apheresis.
Patient group, clinician group, clinical expert, and drug program input gathered in the course of this CADTH review, as well as relevant literature, were reviewed to identify ethical considerations relevant to the use of evinacumab for the treatment of adult and pediatric patients aged 5 years and older with HoFH.
Ethical considerations identified in this review included those related to the following:
Cost and Cost-Effectiveness.
CADTH identified the following key limitations with the sponsor’s analysis: the market shares for evinacumab were likely underestimated, the public drug coverage was likely underestimated, the drug acquisition costs for evinacumab were underestimated, and the inclusion of apheresis costs was inappropriate for the drug plan perspective. The CADTH reanalysis included: revising the market uptake and public drug coverage of evinacumab, accounting for drug wastage and complete compliance, and removing apheresis costs. Based on the CADTH reanalysis, the 3-year budget impact to the public drug plans of introducing evinacumab as an adjunct for the treatment of patients aged 5 years and older with HoFH is expected to be $54,834,025 (year 1: $14,031,446; year 2: $18,188,147; year 3: $22,614,433).
The drug plans filed a request for minor reconsideration of the draft recommendation of evinacumab as an adjunct to diet and other LDL-C–lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with HoFH. In their request, the drug plans identified the following issues:
In the meeting to discuss the drug plans’ request for minor reconsideration, the CDEC subpanel considered the following sources of information:
All stakeholder feedback that was received from clinician groups, patient groups, and the public drug programs in response to the draft recommendation is available on the CADTH website.
Dr. James Silvius (Chair), Dr. Sally Bean, Mr. Dan Dunsky, Dr. Alun Edwards, Mr. Bob Gagne, Dr. Ran Goldman, Dr. Allan Grill, Mr. Morris Joseph, Dr. Christine Leong, Dr. Kerry Mansell, Dr. Alicia McCallum, Dr. Srinivas Murthy, Ms. Heather Neville, Dr. Danyaal Raza, Dr. Emily Reynen, and Dr. Peter Zed.
Meeting date: September 28, 2023
Regrets: None
Conflicts of interest: None
Minor reconsideration CDEC subpanel meeting date: December 22, 2023
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.
CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.
This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.
Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third-party supplier of information.
This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.
This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.
The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for noncommercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.
Redactions: Confidential information in this document may be redacted at the request of the sponsor in accordance with the CADTH Drug Reimbursement Review Confidentiality Guidelines.
About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.
Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Indication: As an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH).
Sponsor: Ultragenyx Pharmaceutical Inc.
Final recommendation: Reimburse with conditions
Copyright © 2024 - Canadian Agency for Drugs and Technologies in Health. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND).
Your browsing activity is empty.
Activity recording is turned off.
See more...
